Astellas Pharma Europe B.V.
Quick facts
Marketed products
- bismuth tripotassium dicitrate
- Locobase® REPAIR · Dermatology
Locobase® REPAIR is an emollient and skin barrier repair product that restores skin hydration and protects damaged skin through occlusive and humectant ingredients.
Phase 3 pipeline
- Fidaxomicin oral suspension · Infectious Disease
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora. - Fidaxomicin tablets · Infectious Disease
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora. - Placebo to match mirabegron · Urology
This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes. - Placebo to match solifenacin succinate · Urology
This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes. - Vancomycin capsules · Infectious Diseases
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. - Vancomycin oral liquid · Infectious Diseases
Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
Phase 2 pipeline
- ASP1128
- ASP3652 · Immunology
ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. - ASP6294 · Immunology
ASP6294 is a small molecule inhibitor of the PI3K delta subunit. - ASP7962 · Immunology
ASP7962 is a small molecule inhibitor of the PI3K delta subunit. - ASP8232 · Immunology
ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. - ASP8477 · Oncology
ASP8477 is a small molecule that targets the CDK9 protein. - Depo-Eligard®
- Other parenteral antifungal drugs
- Parenteral micafungin application
Phase 1 pipeline
- ASP1707 multiple dose of dose levels 1-2
- ASP1707 multiple dose of dose levels 1-4
- ASP1707 single dose fasted
- ASP1707 single dose fed
- ASP1707 single dose of dose levels 1 -7
- ASP6282
- ASP6294 Intravenous
- ASP6294 Subcutaneous
- ASP6858
- ASP7713
- EC905
- YM178 OCAS
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Astellas Pharma Europe B.V.
What are Astellas Pharma Europe B.V.'s marketed drugs?
Top marketed products include bismuth tripotassium dicitrate, Locobase® REPAIR.
What is Astellas Pharma Europe B.V.'s pipeline?
Astellas Pharma Europe B.V. has 6 drugs in Phase 3, 9 in Phase 2, 12 in Phase 1. Late-stage candidates include Fidaxomicin oral suspension, Fidaxomicin tablets, Placebo to match mirabegron, Placebo to match solifenacin succinate.
Related
- bismuth tripotassium dicitrate
- Locobase® REPAIR · Dermatology
- Sector hub: All tracked pharma companies